Zimmer Biomet Holdings 주식 (NYSE: ZBH)

에 대한 최신 뉴스 Zimmer Biomet Holdings (NYSE:ZBH) 주식

Zimmer Biomet Holdings

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings Inc

BTIG analyst Ryan Zimmerman maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Buy and lowers the price target from $134 to $126.

News

Price Target

Analyst Ratings

BTIG Maintains Buy on Zimmer Biomet Holdings, Lowers Price Target to $126

Evercore ISI Group analyst Vijay Kumar maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a In-Line and lowers the price target from $113 to $110.

Evercore ISI Group Maintains In-Line on Zimmer Biomet Holdings, Lowers Price Target to $110

Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) <a href="https://www.fda.gov/medical-devices/safety-communications/zimmer-biomet-cpt-hip-system-femoral-stem-and-increased-risk-thigh-bone-fracture-fda-safety" target="_blank" rel="noreferrer noopener">announced</a> plans to phase out its CPT Hip System by December.
The decision comes on the heels of a warning from the U.S. Food and Drug Administration (FDA), citing research showing a higher risk of postoperative fractures compared to similar hip replacement systems. 
Patients with the CPT Hip System Femoral Stem 12/14 Neck Taper (CPT Hip System) face a 1.4% risk of thigh bone fractures. That&#8217;s higher than the 0.6%-1% fracture rates observed in similar devices.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38949330/orthopedic-implants-maker-zimmer-biomet-gains-analyst-upgrade-amid-promising-growth" rel="noreferrer noopener">Orthopedic Implants Maker Zimmer Biomet Gains Analyst Upgrade Amid Promising Growth From New Products, Demographic Trends</a>.
Zimmer Biomet issued a recall in July to update the instructions for use due to concerns over a heightened fracture risk.
The CPT Hip System, made from cobalt chromium alloy, is a polished-taper slip (PTS) style stem commonly used in hip replacements.
Patients and caregivers are advised to discuss the risks and benefits of hip replacement devices with their healthcare provider, especially if the CPT Hip System is involved.
Those already implanted with the device should remain vigilant for symptoms like pain and difficulty walking. Fractures often require further surgical intervention, which has raised alarm among healthcare providers.
The FDA does not recommend the removal of functioning devices without symptoms. The agency also suggests that healthcare providers consider alternative prostheses when possible. 
The CPT Hip System should only be implanted in new patients when its benefits outweigh the risks or when other options are unavailable.
Price Action: ZBH stock is down 0.78% at $105.41 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40925180/teslas-chinese-competitor-nio-begins-deliveries-of-new-es8-in-europe-amid-eu-tariff-concerns-rep" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Chinese Competitor NIO Begins Deliveries Of New ES8 In Europe Amid EU Tariff Concerns: Report</a>.</li>
</ul>

Large Cap

Health Care

General

Zimmer Biomet To Stop Selling CPT Hip Implant System By End Of 2024 Due To High Fracture Risks

Biotech

FDA Warns Of Increased Risk Of Thigh Bone Fracture After Surgery With Use Of Zimmer Biomet CPT Hip System Femoral Stem 12/14 Ne

Needham analyst Mike Matson reiterates Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Zimmer Biomet Holdings

JP Morgan analyst Robbie Marcus maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Neutral and lowers the price target from $125 to $120.

JP Morgan Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $120

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our<a href="http://benzinga.com/analyst-stock-ratings"> analyst ratings page</a>.
<ul>
<li>Wells Fargo cut the price target for Pebblebrook Hotel Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from $15 to $13. Wells Fargo analyst Dori Kesten maintained an Equal-Weight rating. Pebblebrook Hotel Trust shares rose 1.5% to trade at $12.98 on Friday. S<a href="https://www.benzinga.com/quote/PEB/analyst-ratings">ee how other analysts view this stock.</a></li>
<li>TD Cowen cut the price target for Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from $70 to $60. TD Cowen analyst Tyler Van Buren maintained a Hold rating. Moderna shares fell 4.9% to trade at $66.25 on Friday. <a href="https://www.benzinga.com/quote/mrna/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities cut Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) price target from $117 to $112. Truist Securities analyst Richard Newitter reiterated a Hold rating. Zimmer Biomet shares gained 1.8% to trade at $107.06 on Friday. <a href="https://www.benzinga.com/quote/zbh/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim raised Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) price target from $185 to $200. Guggenheim analyst John Difucci maintained a Buy rating. Oracle shares rose 1% to trade at $162.87 on Friday. <a href="https://www.benzinga.com/quote/orcl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised the price target for TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) from $53 to $60. Goldman Sachs analyst Alexander Blostein maintained a Buy rating. TPG shares gained 3% to close at $55.55 on Friday. S<a href="https://www.benzinga.com/quote/tpg/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>UBS boosted CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) price target from $53 to $54. UBS analyst Michael Goldsmith downgraded the stock from Buy to Neutral. CubeSmart shares fell 0.2% to trade at $53.81 on Friday. <a href="https://www.benzinga.com/quote/cube/analyst-ratings">See how other analysts view this stoc</a>k.</li>
<li>Stifel cut Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) price target from $121 to $103. Stifel analyst Steve Wieczynski maintained a Buy rating. Wynn Resorts shares rose 3.6% to trade at $79.07 on Friday. <a href="https://www.benzinga.com/quote/wynn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut the price target for Nabors Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>) from $110 to $75. Citigroup analyst Scott Gruber downgraded the stock from Buy to Neutral. Nabors Industries shares rose 0.5% to trade at $65.41 on Friday. <a href="https://www.benzinga.com/quote/nbr/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays slashed Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) price target from $181 to $133. Barclays analyst George Wang downgraded the stock from Equal-Weight to Underweight. Garmin shares fell 6.2% to trade at $170.74 on Friday. <a href="https://www.benzinga.com/quote/grmn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group raised The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) price target from $62 to $63. Evercore ISI Group analyst Michael Montani maintained an Outperform rating. Kroger shares rose 1.1% to trade at $55.81 on Friday. <a href="https://www.benzinga.com/quote/kr/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40853112/ionq-is-losing-too-much-money-while-this-tech-stock-is-real-deal-jim-cramer">IonQ Is Losing &#8216;Too Much Money&#8217; While This Tech Stock Is &#8216;Real Deal&#8217;: Jim Cramer</a></li>
</ul>

Markets

Trading Ideas

CUBE

GRMN

MRNA

ORCL

WYNN

Oracle To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Friday

Truist Securities analyst Richard Newitter reiterates Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and lowers the price target from $117 to $112.

Truist Securities Reiterates Hold on Zimmer Biomet Holdings, Lowers Price Target to $112

Canaccord Genuity analyst William Plovanic maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and lowers the price target from $120 to $115.

Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $115

Wolfe Research analyst Mike Polark initiates coverage on Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Zimmer Biomet Holdings with Peer Perform Rating

TD Cowen analyst Joshua Jennings maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and lowers the price target from $143 to $119.

TD Cowen Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $119

Across the recent three months, 14 analysts have shared their insights on Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Zimmer Biomet Holdings, presenting an average target of $121.79, a high estimate of $145.00, and a low estimate of $107.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.29%. 
<img src="https://www.benzinga.com/files/images/story/2024/1725562829_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Zimmer Biomet Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$107.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$113.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$117.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Matthew O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zimmer Biomet Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Zimmer Biomet Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Zimmer Biomet Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zimmer Biomet Holdings analyst ratings.</a>
<h2>Discovering Zimmer Biomet Holdings: A Closer Look</h2>
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
<h3>Zimmer Biomet Holdings: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Zimmer Biomet Holdings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 3.87%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zimmer Biomet Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.5%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Zimmer Biomet Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.92%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Zimmer Biomet Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.13%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Zimmer Biomet Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.46.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 14 Analyst Ratings For Zimmer Biomet Holdings

WIIM

Zimmer Biomet shares are trading lower amid reports the company said the newly implemented ERP will likely impact revenue this year.

Truist Securities analyst Richard Newitter maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and maintains $117 price target.

Truist Securities Maintains Hold on Zimmer Biomet Holdings, Maintains $117 Price Target

Evercore ISI Group analyst Vijay Kumar maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a In-Line and maintains $113 price target.

Evercore ISI Group Maintains In-Line on Zimmer Biomet Holdings, Maintains $113 Price Target

Shares of Zimmer Biomet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) fell sharply on Thursday after the orthopedic device maker said its newly implemented enterprise resource planning (ERP) failed to perform as expected, and the issue is likely to impact its H2 revenue.
At the Wells Fargo 2024 Healthcare Conference on Thursday, CEO Ivan Tornos said that in July, the company switched from its legacy <a href="https://seekingalpha.com/pr/19824426-zimmer-biomet-to-present-wells-fargo-2024-and-morgan-stanley-annual-global-healthcare#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews">ERP platform, DCS, to SAP.</a>
"Things worked well at first, the usual glitches," he noted, adding, "as we get into the August time frame, we identified that it didn't work as expected. That is certainly going to create some challenges when it comes to revenue in the second half of 2024."
Based on current data, Tornos said that the issue will likely impact around 1% of its revenue this year. "By the time we exit Q4, it should be largely resolved," he added.

Rumors

Events

Watching Zimmer Biomet; Traders Circulate CEO Comments Made At The Wells Fargo 2024 Healthcare Conference Saying "Its Newly Implemented Enterprise Resource Planning Failed To Perform As Expected, And The Issue Is Likely To Impact Its H2 Revenue, The Issue Will Likely Impact Around 1% Of Its Revenue This Year And That By The Time We Exit Q4, It Should Be Largely Resolved"

Canaccord Genuity analyst William Plovanic maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and lowers the price target from $130 to $120.

Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $120

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTRS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>4.8K</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$530.00</td>
<td>$167.9K</td>
<td>4.3K</td>
<td>2.1K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$57.50</td>
<td>$25.1K</td>
<td>2.5K</td>
<td>843</td>
</tr>
<tr>
<td>ZBH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$110.00</td>
<td>$56.2K</td>
<td>172</td>
<td>786</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$320.00</td>
<td>$142.5K</td>
<td>879</td>
<td>505</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$185.00</td>
<td>$140.0K</td>
<td>750</td>
<td>218</td>
</tr>
<tr>
<td>DOCS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$80.2K</td>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>ZVRA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$6.00</td>
<td>$46.5K</td>
<td>3</td>
<td>90</td>
</tr>
<tr>
<td>GSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$47.00</td>
<td>$38.4K</td>
<td>3</td>
<td>62</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$75.00</td>
<td>$38.1K</td>
<td>151</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For VTRS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), we notice a call option sweep that happens to be bullish, expiring in 155 day(s) on January 17, 2025. This event was a transfer of 1361 contract(s) at a $13.00 strike. This particular call needed to be split into 62 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $50.0 per contract. There were 2294 open contracts at this strike prior to today, and today 4856 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with bullish sentiment. It expires in 36 day(s) on September 20, 2024. Parties traded 2099 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $167.9K, with a price of $80.0 per contract. There were 4314 open contracts at this strike prior to today, and today 2102 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 64 day(s) on October 18, 2024. Parties traded 100 contract(s) at a $57.50 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $25.1K, with a price of $253.0 per contract. There were 2515 open contracts at this strike prior to today, and today 843 contract(s) were bought and sold. 
• For ZBH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), we notice a put option sweep that happens to be bearish, expiring in 36 day(s) on September 20, 2024. This event was a transfer of 205 contract(s) at a $110.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $56.2K, with a price of $275.0 per contract. There were 172 open contracts at this strike prior to today, and today 786 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option trade with neutral sentiment. It expires in 36 day(s) on September 20, 2024. Parties traded 216 contract(s) at a $320.00 strike. The total cost received by the writing party (or parties) was $142.5K, with a price of $660.0 per contract. There were 879 open contracts at this strike prior to today, and today 505 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a put option sweep with bearish sentiment. It expires in 155 day(s) on January 17, 2025. Parties traded 203 contract(s) at a $185.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $140.0K, with a price of $690.0 per contract. There were 750 open contracts at this strike prior to today, and today 218 contract(s) were bought and sold. 
• Regarding DOCS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), we observe a put option trade with neutral sentiment. It expires in 190 day(s) on February 21, 2025. Parties traded 200 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $80.2K, with a price of $401.0 per contract. There were 0 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For ZVRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>), we notice a call option sweep that happens to be bullish, expiring in 36 day(s) on September 20, 2024. This event was a transfer of 300 contract(s) at a $6.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $46.5K, with a price of $155.0 per contract. There were 3 open contracts at this strike prior to today, and today 90 contract(s) were bought and sold. 
• Regarding GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), we observe a put option sweep with bearish sentiment. It expires in 190 day(s) on February 21, 2025. Parties traded 62 contract(s) at a $47.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $38.4K, with a price of $620.0 per contract. There were 3 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold. 
• Regarding DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we observe a call option trade with bearish sentiment. It expires in 127 day(s) on December 20, 2024. Parties traded 57 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $38.1K, with a price of $670.0 per contract. There were 151 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AMGN

DOCS

DXCM

VRTX

VTRS

ZVRA

10 Health Care Stocks With Whale Alerts In Today's Session

RBC Capital analyst Shagun Singh maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $140 to $130.

RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $130

Raymond James analyst Jayson Bedford maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $138 to $128.

Raymond James Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $128

American Century Mid Cap Value Fund Q2 2024 Commentary

Zimmer Biomet Stock: Don't Jump In At The 52-Week Low

American Century Value Fund Q2 2024 Commentary

Zimmer Biomet Still Not There Yet With Respect To Consistency And Share Recoveries

The Top Five short crowded stocks in each U.S. sector

Piper Sandler Sticks to Its Hold Rating for Zimmer Biomet Holdings (ZBH)

Pioneer Disciplined Value Fund Q2 2024 Performance And Market Commentary

Pioneer Mid Cap Value Fund Q2 2024 Performance And Market Commentary

Zimmer Biomet: The Undervalued Titan Of Joint Replacements

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price ...

Zimmer Biomet Holdings (ZBH) Gets a Buy from Stifel Nicolaus

ADRNY

AEMB

AGCO

AHODF

AHYB

APLE

ASIX

AVNW

BACRP

BEPC

BIRD

BMBL

CABO

CBRL

CBSH

CERT

CHRD

CMSA

CMSC

CMSD

CMTL

CSCO

CTRA

EBAY

ECVT

EPDU

ESGA

ESGY

EVTC

FUSI

GEHC

HSIC

IART

INST

INTC

KEYS

KORP

MNTK

NAPA

NEWT

NTRS

NTRSO

NTST

NVDA

NXDT

OASPW

PDCO

QCOM

QCON

QGRO

QINT

QPFF

REXR

RHHBF

RYDAF

SDSI

SHEL

SIRI

TAXF

TROW

ULCC

VALQ

VTLE

WLLAW

WLLBW

XRAY

Screenshot 2024-03-27 at 5.33.58 PM

NMTC

NeuroOnes&#39;s Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders

Press Releases

Zimmer Biomet to Present at the Goldman Sachs 45th Annual Healthcare Conference

Zimmer Biomet Enters Distribution Agreement with THINK Surgical to Offer TMINI® Miniature Handheld Robotic System for Total Knee Arthroplasty

RevelAi Health and Zimmer Biomet Announce Exclusive Multi-Year Co-Marketing Agreement to Advance Value-Based Care and Health Equity through AI-Powered Technology

Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2024 Financial Results

Earnings

Zimmer Biomet Announces Second Quarter 2024 Financial Results

Zimmer Biomet Signs Definitive Agreement to Acquire OrthoGrid Systems, Inc.

Zimmer Biomet to Present at the Wells Fargo 2024 and Morgan Stanley Annual Global Healthcare Conferences

Dividends

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024

Zimmer Biomet Names David DeMartino as Senior Vice President, Investor Relations

Comments

Zimmer Biomet Holdings

뉴스

에 대한 최신 뉴스 Zimmer Biomet Holdings (NYSE:ZBH) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌